Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2008
01/24/2008WO2006135733A3 Modulation of peripheral clocks in adipose tissue
01/24/2008WO2006133257A3 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
01/24/2008WO2006107902A8 Use of spirostenols to treat mitochondrial disorders
01/24/2008WO2006093526A3 Oligonucleotides comprising a modified or non-natural nucleobase
01/24/2008WO2006029371A3 Neuromedin u 2 receptor agonists and uses thereof
01/24/2008WO2005120578A3 Biodegradable drug-polymer delivery system
01/24/2008WO2005120576A3 Composition and method for improving pancreatic islet cell survival
01/24/2008WO2005069982A3 Wound treatment composition and process of manufacture
01/24/2008WO2005030779A3 Laulimalide analogs with anti-cancer activitity
01/24/2008WO2004103299A3 Compositions and methods for the treatment of cns injuries
01/24/2008WO2003101437A3 Method of treating asthma using fexofenadine
01/24/2008US20080021561 Spine distraction implant and method
01/24/2008US20080021560 Spine distraction implant and method
01/24/2008US20080021244 Levalbuterol hydrochloride Polymorph A
01/24/2008US20080021227 Antineoplastic cocoa extracts and methods for making and using the same
01/24/2008US20080021217 Heterocyclic inhibitors of rho kinase
01/24/2008US20080021211 Rapamycin analogues; diabetes, acute or chronic rejection of an organ or tissue transplant, asthma, tumours, psoriasis, eczema, rheumatoid arthritis, fibrosis, and allergies
01/24/2008US20080021196 Inhibitors of memapsin 2 and use thereof
01/24/2008US20080021112 Long chain alcohols provided in edible oils
01/24/2008US20080021111 administering to a patient in need thereof an effective amount of fispemifene wherein said chronic nonbacterial prostatitis is not associated with urethral sphincter dysfunction
01/24/2008US20080021110 Producing (-)-gossypol acetic acid co-crystals from (-)-gossypol acetone co-crystals, by substituting acetone in (-)-gossypol acetone co-crystals with acetic acid; use of gossypol acetic acid co-crystals and (-)-gossypol acetic acid co-crystals for inducing and for sensitizing cells to apoptosis
01/24/2008US20080021109 5-[3-(2,6-Dimethylbenzyloxy)-phenyl]-pent-4-enoic acid ethyl ester; insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis, arteriosclerosis; side effects reduction; orally active
01/24/2008US20080021108 Memory Fixation Accelerator
01/24/2008US20080021107 Use of amino acids for treatment of various conditions
01/24/2008US20080021106 Cellular uptake of bioactive agents
01/24/2008US20080021105 Medicine Capable of Inhibiting Activation of Transcription Factor Klf5
01/24/2008US20080021104 Liquid compositions of calcium acetate
01/24/2008US20080021103 Mucoadhesive composition
01/24/2008US20080021102 Method for the Management of Incontinence
01/24/2008US20080021101 Method Of Preparing A Latanoprost Opthalmic Solution And The Resulting Solution
01/24/2008US20080021100 Pharmaceutical Formulations and Compositions of a Selective Antagonist of Either CXCR2 or Both CXCR1 and CXCR2 and Methods of Using the Same for Treating Inflammatory Disorders
01/24/2008US20080021099 5-Cyano-prostacyclin derivatives as agents for the treatment of autoimmune disease
01/24/2008US20080021097 Arginase levels/activity
01/24/2008US20080021096 Methods of using flavonoids to enhance memory
01/24/2008US20080021095 Small Molecule Antagonists of Xiap Family Proteins
01/24/2008US20080021094 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
01/24/2008US20080021092 Stable pharmaceutical compositions of orlistat
01/24/2008US20080021091 Crystalline duloxetine hydrochloride
01/24/2008US20080021090 dissolving duloxetine in a first organic solvent (e.g.ethyl acetate) to form a first solution; adding the first solution to a second organic solvent (e.g.ethanol) comprising HCl to form a second solution;allowing duloxetine hydrochloride to crystallize out from second solution; collecting the product
01/24/2008US20080021089 Crystalline duloxetine hydrochloride
01/24/2008US20080021088 Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities
01/24/2008US20080021087 Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders
01/24/2008US20080021086 Administering mitglinide or mitglinide calcium hydrate; hypertriglyceridemia; hypercholesterolemia; hyperlipidemia; anticholesteraol agents; antidiabetic agents; glucose intolerance; non-insulin dependendent diabetes; side effect reduction; cardiovascular disorders
01/24/2008US20080021085 Method of reducing abeta42 and treating diseases
01/24/2008US20080021084 Derivatives Of Pyrazoline, Procedure For obtaining Them And Use Thereof As Therapeutic Agents
01/24/2008US20080021083 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
01/24/2008US20080021082 Small molecule inhibition of a PDZ-domain interaction
01/24/2008US20080021081 e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis
01/24/2008US20080021080 4-(3-{[4-(4-Ethyl-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phenyl]thio}phenyl)tetrahydro-2H-pyran-4-carboxamide (Compound No. 1); bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease
01/24/2008US20080021079 Compounds, Compositions, and Methods
01/24/2008US20080021078 Methods and medicaments for administration of ibuprofen
01/24/2008US20080021077 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole
01/24/2008US20080021076 Treatment of Pain
01/24/2008US20080021075 Treatment of Pain
01/24/2008US20080021074 Pharmaceutical Compositions and Related Methods of Treatment
01/24/2008US20080021073 Novel heterocyclic compounds
01/24/2008US20080021072 Porous plastic smoking cessation devices
01/24/2008US20080021071 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
01/24/2008US20080021070 Pyridine derivatives, preparation and therapeutic application thereof
01/24/2008US20080021069 Receptor Function Regulating Agent
01/24/2008US20080021068 Aqueous gel formulation and method for inducing topical anesthesia
01/24/2008US20080021067 Methods For The Treatment Of Substance Abuse And Addiction
01/24/2008US20080021066 Iap inhibitors
01/24/2008US20080021065 Novel benzamidine compound
01/24/2008US20080021064 Novel cyclic compound having quinolylalkylthio group
01/24/2008US20080021063 Compositions and methods for modulating sirtuin activity
01/24/2008US20080021062 Alkylsulphonamide Quinolines
01/24/2008US20080021061 Tetrahydropyranyl Cyclopentyl Tetrahydropyridopyridine Modulators of Chemokine Receptor Activity
01/24/2008US20080021060 Quinuclidine carbamate derivatives and their use as M3 antagonists
01/24/2008US20080021059 Antibacterial Agents
01/24/2008US20080021058 Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors
01/24/2008US20080021057 3-Trifluoromethyl,6-((3-(methyl,4-hydroxytetrahydropyran-4-yl)-amino-(3-isopropyl-cyclopent-1,3-ylene))-carbonyl-)-5,6,7,8-tetrahydro-1,6-naphthyridine; antiinflammatory agents; immunomodulators; antiallergens; rhintis; dermatitis; conjunctivits, asthma; autoimmune diseases; antiarthritis agents
01/24/2008US20080021056 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase
01/24/2008US20080021055 Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
01/24/2008US20080021054 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
01/24/2008US20080021053 Heterocyclic Derivatives
01/24/2008US20080021052 Novel glucokinase activators and methods of using same
01/24/2008US20080021051 Phycotoxins and Uses Thereof
01/24/2008US20080021050 Compounds, compositions, and methods
01/24/2008US20080021049 Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds
01/24/2008US20080021048 such as 8-(2-Fluorophenylamino)-2-(4-methoxyphenylamino)-9-(trans-4-(methylamino)cyclohexyl)-9H-purine, used for for inhibiting neutrophil accumulation in bronchoalveolar lavage fluid
01/24/2008US20080021047 C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase
01/24/2008US20080021046 USE OF 8-SUBSTITUTED-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
01/24/2008US20080021044 N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2h)-pyrazineacetamide
01/24/2008US20080021043 Piperidines and Related Compounds for Treatment of Alzheimer's Disease
01/24/2008US20080021042 Composition For Controlling Neuropathic Pain
01/24/2008US20080021041 4-piperazinyl-2-phenyl-1-(benzylaminocarbonyl)piperidine derivatives; treatment of conditions mediated by tachykinins, especially emesis, CNS disorders, various kinds of pain, sleep disorders, gastrointestinal disorders and cognitive disorders
01/24/2008US20080021040 Method and composition for treating periodontal disease
01/24/2008US20080021039 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-[4-(4-methylpiperazin-1-yl-sulfonyl)-phenyl]-3H-imidazo-[4,5-b]pyridine,; acute inflammatory diseases: Septic shock, sepsis, SIRS, hemorrhagic shock, organ transplantation and transplant rejection, head trauma, acute lung injury
01/24/2008US20080021038 Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5
01/24/2008US20080021037 Isethionate salt of a selective cdk4 inhibitor
01/24/2008US20080021036 Administering a composition comprising a therapeutically effective amount of a protein kinase C zeta inhibitor; treatment of abnormal permeability of vascular tight junctions
01/24/2008US20080021035 Myosin light chain kinase inhibitor compounds, compostions and related methods of use
01/24/2008US20080021034 Compositions and methods for modulating gated ion channels
01/24/2008US20080021033 Immuno Inhibitory Heterocyclic Compounds
01/24/2008US20080021032 Pyrazole glucokinase activators
01/24/2008US20080021031 Selenophene compounds
01/24/2008US20080021030 Substituted Pyrazoles As Ppar Agonists
01/24/2008US20080021029 Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors
01/24/2008US20080021028 ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis